Kyowa Hakko Kirin Cancer Drugs Clinical Pipeline Insight

Publish Date:- Nov-2016       No Of Pages (181)

Electronic Access - Single User License $800 Buy Now
CD-ROM Mail Delivery $1200Buy Now
Hard Copy Mail Delivery $1200 Buy Now
Electronic Access - Multi-User License $1600 Buy Now


“Kyowa Hakko Kirin - Cancer Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Kyowa Hakko Kirin. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “33” cancer drugs in clinical pipeline and majority of them are in preclinical phase. There are 11 cancer drugs by Kyowa Hakko Kirin which are commercially available in the market.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Kyowa Hakko Kirin - Cancer Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.


“Kyowa Hakko Kirin - Cancer Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Kyowa Hakko Kirin. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “33” cancer drugs in clinical pipeline and majority of them are in preclinical phase. There are 11 cancer drugs by Kyowa Hakko Kirin which are commercially available in the market.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Kyowa Hakko Kirin - Cancer Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.

1. Kyowa Hakko Kirin

  1.1 Business Overview

  1.2 Kyowa Hakko Kirin Cancer Pipeline Overview

 

2. Kyowa Hakko Kirin Cancer Drugs in Research Phase

  2.1 Dendritic Cell Vaccines - Argos/Kyowa Hakko Kirin

  2.2 Wnt Signalling Pathway Inhibitors - Kyowa Hakko Kirin

  2.3 Anticancer Therapeutics - Cancer Science Institute of Singapore/Kyowa Hakko Kirin//National University Cancer Institute Singapore

 

3. Kyowa Hakko Kirin Cancer Drugs in Preclinical Phase

  3.1 KRN 5500

  3.2 IL1RAP Antibody Therapeutics - Cantargia

  3.3 KHK 2455

  3.4 KHK 2805

  3.5 IT 1208

  3.6 Monoclonal Antibody Therapeutics - arGEN-X/Bird Rock Bio

  3.7 Dicer Substrate siRNA Therapeutics - Dicerna/Kyowa Hakko Kirin

  3.8 Anti-Cancer Protein Therapeutics - Five Prime Therapeutics

  3.9 Antibody-Based Cancer Therapeutics - Menarini/Oxford BioTherapeutics

  3.10 Antibody-Based Cancer Therapies - Medarex/Oxford BioTherapeutics

  3.11 Antibody-Based Cancer Therapies - Amgen/Oxford BioTherapeutics

  3.12 Monoclonal Antibodies - ImmunoCellular Therapeutics

  3.13 Natural Killer T Cell-Based Therapeutics - NKT Therapeutics

 

4. Kyowa Hakko Kirin Cancer Drugs in Phase-I

  4.1 Utomilumab

  4.2 GLPG 0187

  4.3 KHK 2823

  4.4 OBT 357

  4.5 ARGX 111

  4.6 ARGX 110

 

 5. Kyowa Hakko Kirin Drugs in Phase-I/II

  5.1 Lenzilumab

 

6. Kyowa Hakko Kirin Cancer Drugs in Phase-II

  6.1 Bemiparin Sodium

  6.2 BIW 8962

  6.3 KB 004

 

7. Kyowa Hakko Kirin Cancer Drugs in Phase-III

  7.1 Darbepoetin Alfa

  7.2 Durvalumab

  7.3 Entinostat

  7.4 Tivantinib

  7.5 Lestaurtinib

 

8. Kyowa Hakko Kirin Cancer Drugs in Preregistration Phase

  8.1 Tivozanib

  8.2 Rituximab biosimilar - Sandoz

 

9. Marketed Cancer Drugs in Kyowa Hakko Kirin

  9.1 Nivolumab

  9.2 Vinorelbine

  9.3 Mogamulizumab

  9.4 Carmustine Polifeprosan 20 Wafer

  9.5 Toremifene

  9.6 Doxorubicin - Kyowa Hakko Kirin

  9.7 Amsacrine

  9.8 Altretamine

  9.9 Asparaginase Escherichia coli-derived - Kyowa Hakko Kirin

  9.10 Temoporfin

  9.11 Mogamulizumab Companion Diagnostics - Kyowa Medex

 

10. No Development Reported In Cancer Drugs in Clinical Pipeline

  10.1 TRAIL-R2 Monoclonal Antibody Therapeutic

  10.2 MDX 1401

  10.3 GNX 8

  10.4 fms-Like Tyrosine Kinase 3 Inhibitors - Kyowa Hakko Kirin

  10.5 Tyrosine Kinase Inhibitors - Kyowa Hakko Kirin

  10.6 Anticancer Monoclonal Antibodies - MedImmune/Georgetown University

  10.7 Anti-FLT-1 Monoclonal Antibody – BioWa

  10.8 Bispecific Antibody Therapeutics - Genmab/Kyowa Hakko Kirin

  10.9 Anticancer Monoclonal Antibodies - GlaxoSmithKline/Oxford BioTherapeutics

 

11. Discontinued In Cancer Drugs in Clinical Pipeline

  11.1 Bardoxolone Methyl

  11.2 Ecromeximab

  11.3 Alpha Galactosylceramide - Kyowa Hakko Kirin

  11.4 FO 152

  11.5 KW 2450

  11.6 KW 2449

  11.7 KRN 330

  11.8 AGS 005

  11.9 KHK 2866

  11.10 KHK 2898

  11.11 CEP 37250

  11.12 Anti-FGF8 Monoclonal Antibody – BioWa

  11.13 Anti-Ganglioside GD2 Monoclonal Antibodies - BioWa

  11.14 Secreted Protein Therapeutics - ARCA biopharma/Kyowa Hakko Kirin

  11.15 Anticancer Therapeutics - BioWa/OncoTherapy Science

  11.16 FO 439


Figure 1-1: Kyowa Hakko Kirin Cancer Pipeline by Phase (%)

Figure 1-2: Kyowa Hakko Kirin Cancer Pipeline by Phase (Number)

Figure 1-3: Kyowa Hakko Kirin Cancer Drugs Discontinued & No Development Reported in Clinical Pipeline by Phase (%)

Figure 1-4: Kyowa Hakko Kirin Cancer Drugs Discontinued & No Development Reported in Clinical Pipeline by Phase (Number)